Can Semaglutide Cause a UTI? What the Evidence Actually Shows

What the clinical data says about semaglutide and urinary tract infections

The short answer is: very little. Urinary tract infections do not appear in the list of common (affecting more than 1 in 100 people) or uncommon side effects for semaglutide in its licensed weight-management form. The NHS medicines page for semaglutide covers the known side-effect profile in plain language, and UTIs are not among them. The STEP 1 trial (68 weeks, nearly 2,000 adults, semaglutide 2.4mg versus placebo) produced a detailed safety dataset and did not flag urinary infections as a signal worth tracking. That is meaningful. Clinical trials at that scale are specifically designed to pick up patterns that would otherwise be invisible.

The confusion often arises from two places. First, Ozempic (the same molecule, different dose, licensed for type 2 diabetes rather than weight loss) is sometimes discussed alongside SGLT-2 inhibitors, which genuinely do raise UTI risk as part of their mechanism. If someone switched from an SGLT-2 inhibitor to semaglutide and then developed a UTI, the timeline can look causal even when it probably is not. Second, online forums surface individual experiences that carry no denominator: you read ten people saying semaglutide gave them a UTI, but you do not read about the thousands for whom it never happened. That is not a reason to dismiss the reports, but it is a reason not to treat them as evidence of a direct effect.

Our semaglutide overview covers the full licensed side-effect picture in the UK context, which is useful background before a consultation.

Why some people on semaglutide may be more prone to UTIs, indirect factors

The more useful question is not whether semaglutide causes UTIs but whether being on it creates conditions that make them more likely. There are a few plausible indirect routes.

Nausea is the most common early side effect, and when you feel sick you drink less. Reduced fluid intake is one of the best-established risk factors for UTIs, concentrated urine, less frequent voiding, bacteria that do not get flushed out. This is not a pharmacological effect of semaglutide on your urinary tract; it is a downstream consequence of feeling rough in the first few weeks. The fix is practical: keeping fluids up even when appetite and thirst are suppressed. If that is harder than it sounds, gastrointestinal side effects more broadly are worth understanding so you know what to expect and when they typically ease.

People who start semaglutide for weight management often have one or more conditions that independently elevate UTI risk, prediabetes, type 2 diabetes, or a history of recurrent infections. A UTI that appears a month into treatment may simply reflect a pre-existing vulnerability rather than a new one. Your prescriber needs to know your history precisely because these overlapping risks are not always obvious from a questionnaire alone.

When to act on urinary symptoms and what to tell your prescriber

A UTI during semaglutide treatment does not automatically mean you need to stop. Most UTIs are straightforward bacterial infections that respond to a short antibiotic course. What matters is not ignoring the symptoms. Burning on urination, frequency, cloudy or strong-smelling urine, or pelvic discomfort are all reasons to contact your GP promptly, do not wait until your next prescription review to mention it.

If you have had recurrent UTIs in the past and are considering semaglutide, bring that history to your consultation. A prescriber will weigh it alongside everything else: your BMI, your other conditions, your current medicines. It is rarely a reason to rule out treatment, but it may change the advice around hydration and monitoring.

For broader questions about what happens during treatment (including managing UTI symptoms specifically while on Wegovy or understanding why some people associate Wegovy with UTIs) we have covered both in detail. And if you are curious about other symptoms that occasionally get attributed to semaglutide, our page on semaglutide and erectile dysfunction follows the same evidence-led approach.

Making your decision: semaglutide suitability is a clinical question, not a checklist

If you have landed here because you are trying to decide whether UTI risk should put you off semaglutide, here is the honest position: the direct evidence for a causal link is thin, the indirect risks are manageable with straightforward hygiene and hydration habits, and your individual health history is what actually drives the answer. That is not a hedge, it is why a prescriber's assessment exists. A UTI history alone is not a contraindication in the SmPC.

Cost is sometimes part of the decision too. Wegovy pricing in the private market varies, and understanding what you are actually paying for helps. Our Wegovy cost breakdown covers what a transparent private price should include, without glossing over the numbers. If you are ready to talk through whether semaglutide fits your situation, the consultation at our treatment page is free and reviewed by a GPhC-registered prescriber the same day, a real clinician reads your answers, not an automated system. The MHRA's Yellow Card scheme is also there if you experience something unexpected during treatment and want to report it.